These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7706173)

  • 21. [A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group].
    Gobernado M; Bouza E; Perea E; Alvarez-Bravo J; García Rodríguez JA
    Rev Esp Quimioter; 1998 Jun; 11(2):139-46. PubMed ID: 9795299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
    Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
    Duez JM; Siebor E; Pechinot A; Cordin X; Chamard-Neuwirth C; Kazmierczak A
    Pathol Biol (Paris); 1995 Mar; 43(3):208-14. PubMed ID: 7675548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units.
    Bonfiglio G; Laksai Y; Franceschini N; Perilli M; Segatore B; Bianchi C; Stefani S; Amicosante G; Nicoletti G
    Chemotherapy; 1998; 44(5):305-12. PubMed ID: 9732144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.
    Simor AE; Louie L; Louie M
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):521-3. PubMed ID: 7957281
    [No Abstract]   [Full Text] [Related]  

  • 32. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
    Okhuysen PC; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.
    Schwaber MJ; Graham CS; Sands BE; Gold HS; Carmeli Y
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1882-6. PubMed ID: 12760862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases].
    Alarcón T; de la Obra P; López-Hernandez S; de las Cuevas C; López-Brea M
    Rev Esp Quimioter; 1999 Sep; 12(3):229-33. PubMed ID: 10878513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
    Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
    Frei CR; Hampton SL; Burgess DS
    Clin Ther; 2006 Jul; 28(7):1035-40. PubMed ID: 16990081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
    Higashitani F; Nishida K; Hyodo A; Inoue M
    J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.